LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 587

Search options

  1. Article ; Online: Helicobacter pylori Infection and Pathogenic Variants in Homologous Recombination Genes in Gastric Cancer.

    Nguyen, Tra Ly / Mégraud, Francis / Varon, Christine

    Clinical chemistry

    2024  Volume 70, Issue 1, Page(s) 21–24

    MeSH term(s) Humans ; Stomach Neoplasms/genetics ; Helicobacter Infections/genetics ; Helicobacter pylori/genetics
    Language English
    Publishing date 2024-01-10
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1093/clinchem/hvad140
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Antibiotic Resistance Is the Key Element in Treatment of Helicobacter pylori Infection.

    Mégraud, Francis

    Gastroenterology

    2018  Volume 155, Issue 5, Page(s) 1300–1302

    MeSH term(s) Anti-Bacterial Agents ; Clarithromycin ; Drug Resistance, Bacterial/drug effects ; Drug Resistance, Microbial/drug effects ; Helicobacter Infections ; Helicobacter pylori/drug effects ; Humans
    Chemical Substances Anti-Bacterial Agents ; Clarithromycin (H1250JIK0A)
    Language English
    Publishing date 2018-10-08
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2018.10.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Microbiota and gastric cancer.

    Bessède, Emilie / Mégraud, Francis

    Seminars in cancer biology

    2022  Volume 86, Issue Pt 3, Page(s) 11–17

    Abstract: The discovery of Helicobacter pylori in 1982 drew to an end the stomach being considered as a sterile organ. Later, the progress in molecular methods, especially Next Generation Sequencing and metagenomics, has highlighted the fact that a diverse ... ...

    Abstract The discovery of Helicobacter pylori in 1982 drew to an end the stomach being considered as a sterile organ. Later, the progress in molecular methods, especially Next Generation Sequencing and metagenomics, has highlighted the fact that a diverse microbiota including five major phyla could also be present in the stomach. However, when present, H. pylori is the essential species and it influences the other bacterial communities in terms of richness and evenness. It is now well accepted that H. pylori is the main risk factor for gastric cancer, especially the strains harboring the cag pathogenicity island and the CagA oncoprotein, but the need for other factors from the host and the environment can explain the important difference between those infected and those developing gastric cancer. Several studies showed a difference between the gastric microbiota of patients at various stages of development of gastric premalignant and malignant lesions, showing globally a reduced microbial diversity and an increase in the presence of intestinal commensals, especially with nitrosative functions. Other studies showed an increase in oral microbiota. These data suggest that the gastric microbiota other than H. pylori may play a role in the last steps of gastric carcinogenesis. It must also be noted that in a limited number of cases, a virus: the Epstein Barr Virus is responsible for the evolution toward gastric cancer, while in others the mycobiota also needs to be explored. Finally, the use of mice models allowed an exploration of the role of different gastric microbiota in addition to H. pylori.
    MeSH term(s) Humans ; Mice ; Animals ; Stomach Neoplasms/etiology ; Helicobacter Infections/complications ; Helicobacter Infections/microbiology ; Helicobacter Infections/pathology ; Epstein-Barr Virus Infections/complications ; Herpesvirus 4, Human ; Helicobacter pylori/genetics ; Microbiota
    Language English
    Publishing date 2022-05-06
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1033980-2
    ISSN 1096-3650 ; 1044-579X
    ISSN (online) 1096-3650
    ISSN 1044-579X
    DOI 10.1016/j.semcancer.2022.05.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Time to change approaches to Helicobacter pylori management.

    Mégraud, Francis

    The lancet. Gastroenterology & hepatology

    2017  Volume 2, Issue 10, Page(s) 692–693

    Language English
    Publishing date 2017-10
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2468-1253
    ISSN (online) 2468-1253
    DOI 10.1016/S2468-1253(17)30245-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: 30th anniversary of the European helicobacter & microbiota study group!

    Mégraud, Francis

    Helicobacter

    2017  Volume 22 Suppl 1

    MeSH term(s) Animals ; Helicobacter Infections/microbiology ; Helicobacter pylori/genetics ; Helicobacter pylori/physiology ; Humans ; Microbiota
    Language English
    Publishing date 2017-08-26
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 1330665-0
    ISSN 1523-5378 ; 1083-4389
    ISSN (online) 1523-5378
    ISSN 1083-4389
    DOI 10.1111/hel.12422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Culture-Based Antimicrobial Susceptibility Testing for Helicobacter pylori.

    Lehours, Philippe / Mégraud, Francis

    Methods in molecular biology (Clifton, N.J.)

    2021  Volume 2283, Page(s) 45–50

    Abstract: Culture-based antimicrobial susceptibility testing is a crucial method for the management of Helicobacter pylori infection . It must follow the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations for fastidious ... ...

    Abstract Culture-based antimicrobial susceptibility testing is a crucial method for the management of Helicobacter pylori infection . It must follow the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations for fastidious microaerophilic bacteria, with some possible variation especially for the medium to be used. It is recommended to test six antibiotics by diffusion using strips charged with an antibiotic gradient in order to determine the minimum inhibitory concentrations (MICs). Two of these antibiotics, clarithromycin and levofloxacin, are more important because of frequent resistance which jeopardizes the success of the treatment.
    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Clarithromycin/pharmacology ; Culture Media ; Disk Diffusion Antimicrobial Tests/methods ; Drug Resistance, Multiple, Bacterial ; Helicobacter Infections/drug therapy ; Helicobacter Infections/microbiology ; Helicobacter pylori/drug effects ; Helicobacter pylori/growth & development ; Humans ; Levofloxacin/pharmacology
    Chemical Substances Anti-Bacterial Agents ; Culture Media ; Levofloxacin (6GNT3Y5LMF) ; Clarithromycin (H1250JIK0A)
    Language English
    Publishing date 2021-03-25
    Publishing country United States
    Document type Journal Article
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-0716-1302-3_6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Molecular Diagnosis for Helicobacter pylori . . . at Last.

    Mégraud, Francis / Bessède, Emilie

    Gastroenterology

    2021  Volume 161, Issue 5, Page(s) 1367–1369

    MeSH term(s) Helicobacter Infections/diagnosis ; Helicobacter pylori ; Humans
    Language English
    Publishing date 2021-08-12
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2021.08.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Failed Eradication for Helicobacter pylori. What Should Be Done?

    Mégraud, Francis

    Digestive diseases (Basel, Switzerland)

    2016  Volume 34, Issue 5, Page(s) 505–509

    Abstract: Failed eradication of Helicobacter pylori occurs when the antibiotic concentration at the site where H. pylori is located is lower than the minimal inhibitory concentration of the antibiotic for this bacterium. The main reason for this is the acquisition ...

    Abstract Failed eradication of Helicobacter pylori occurs when the antibiotic concentration at the site where H. pylori is located is lower than the minimal inhibitory concentration of the antibiotic for this bacterium. The main reason for this is the acquisition of resistance; and in the context of the most common treatment, the main reason is the acquisition of resistance to clarithromycin. Several options can then be followed. The most rational option is to use a tailored therapy, that is, to look for clarithromycin resistance either by culture plus antibiogram or by a molecular method. The standard triple therapy is used only in the case of clarithromycin susceptibility. In case of resistance or if an empiric treatment must be given, a good option is to use a bismuth-based quadruple therapy. If unavailable, clarithromycin-based quadruple therapies can be used either as sequential or 'concomitant' or hybrid. The limit, especially for concomitant therapy, is the use of clarithromycin, which will be inactive in about 2/3 of the cases, adding to cost and adverse events. Recently, the dual therapy proton pump inhibitor-amoxicillin has been revisited especially in the Far East, and increasing the dose and the frequency of administration gives excellent results.
    MeSH term(s) Bismuth ; Clarithromycin/administration & dosage ; Drug Resistance, Bacterial ; Drug Therapy, Combination ; Helicobacter Infections/drug therapy ; Helicobacter Infections/microbiology ; Helicobacter pylori/drug effects ; Humans ; Microbial Sensitivity Tests ; Proton Pump Inhibitors/therapeutic use ; Treatment Failure
    Chemical Substances Proton Pump Inhibitors ; Clarithromycin (H1250JIK0A) ; Bismuth (U015TT5I8H)
    Language English
    Publishing date 2016
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 632798-9
    ISSN 1421-9875 ; 0257-2753
    ISSN (online) 1421-9875
    ISSN 0257-2753
    DOI 10.1159/000445230
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Sequential versus Standard Triple Therapy for First-Line

    Nyssen, Olga P / Martínez, Belén / Mégraud, Francis / Savarino, Vincenzo / Fallone, Carlo A / Bazzoli, Franco / Gisbert, Javier P

    Antibiotics (Basel, Switzerland)

    2024  Volume 13, Issue 2

    Abstract: Background: non-bismuth sequential therapy (SEQ) was suggested as a first-line anti-: Methods: We conducted a systematic review with a meta-analysis of randomized controlled trials (RCTs) comparing the efficacy of 10-day SEQ vs. STT (of at least 7 ... ...

    Abstract Background: non-bismuth sequential therapy (SEQ) was suggested as a first-line anti-
    Methods: We conducted a systematic review with a meta-analysis of randomized controlled trials (RCTs) comparing the efficacy of 10-day SEQ vs. STT (of at least 7 days) using bibliographical searches up to July 2021, including treatment-naïve adult or children. The intention-to-treat (ITT) eradication rate and the risk difference (RD) were calculated.
    Results: Overall, 69 RCTs were evaluated, including 19,657 patients (9486 in SEQ; 10,171 in STT). Overall, SEQ was significantly more effective than STT (82% vs. 75%; RD 0.08;
    Conclusions: Prior to 2010, SEQ was significantly more effective than STT, notably when 7-day STT was prescribed. A tendency toward lower differences between SEQ and STT has been noted, especially when using 10-day STT. None of the therapies achieved an optimal efficacy and therefore cannot be recommended as a valid first-line
    Language English
    Publishing date 2024-01-30
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics13020136
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Empiric use of standard triple therapy in

    Malfertheiner, Peter / Megraud, Francis / Rokkas, Theodore / Gisbert, Javier P

    Gut

    2024  Volume 73, Issue 4, Page(s) 708–709

    MeSH term(s) Humans ; Clarithromycin/therapeutic use ; Helicobacter pylori ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Helicobacter Infections/drug therapy ; Drug Therapy, Combination ; Amoxicillin/therapeutic use ; Proton Pump Inhibitors/therapeutic use ; Drug Resistance, Bacterial ; Metronidazole/therapeutic use
    Chemical Substances Clarithromycin (H1250JIK0A) ; Anti-Bacterial Agents ; Amoxicillin (804826J2HU) ; Proton Pump Inhibitors ; Metronidazole (140QMO216E)
    Language English
    Publishing date 2024-03-07
    Publishing country England
    Document type Letter
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2023-329712
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top